Lilly's First Type II JAK2 Inhibitor Phase 1 Study Shows 70% of Patients Achieve Spleen Reduction
Eli Lilly and Company (Lilly) has announced the first clinical data for its investigational drug AJ1...
Johnson & Johnson's TALVEY Combination Therapy Reduces Risk of Myeloma Progression or Death by 72%
Data from the MonumenTAL-3 clinical trial show that Tal-DP and Tal-D regimens significantly prolonge...
ENDO 2026: Menopausal Hormone Therapy Reduces Risk of Low Bone Density by 69%
A study presented at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Illinois, USA, fo...
China's Akeso's Gumokimab Approved by NMPA for Moderate-to-Severe Plaque Psoriasis
Akeso (9926.HK) announced that the China National Medical Products Administration (NMPA) has approve...
China and Platinum Appoints Patel as Scientific Advisor
Harbour BioMed (HKEx: 02142) announced the appointment of Dr. Dhavalkumar Patel as a scientific advi...
China Unicom Launches Billion-Yuan Support Plan for High-Quality Datasets
At a recent milestone achievement conference held in Beijing, the National Artificial Intelligence A...
Chinese Scientists Propose "Pulsatile Activation" Concept and Develop New Drug for Chronic Liver Disease
The team led by Xu Huaqiang and Li Jia from the Shanghai Institute of Materia Medica, Chinese Academ...
SK Bioscience of South Korea Licenses Rotavirus Vaccine Technology from US CDC
SK bioscience has initiated process development for an injectable rotavirus vaccine candidate. The c...
Switzerland's VERAXA Biotech to List on Nasdaq
VERAXA Biotech AG announced the completion of its business combination with Voyager Acquisition Corp...
Chinese Team's RNA Editing Therapy Shows Efficacy in Treating Rare Disease
A team led by Wei Wensheng, a leading scientist at Changping Laboratory and a professor at Peking Un...